Savella is owned by Allergan.
Savella contains Milnacipran Hydrochloride.
Savella has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Savella are:
Savella was authorised for market use on 14 January, 2009.
Savella is available in tablet;oral dosage forms.
Savella can be used as management of fibromyalgia, management of fibromyalgia (fm).
The generics of Savella are possible to be released after 19 September, 2029.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US6602911||ALLERGAN||Methods of treating fibromyalgia|| |
(13 days ago)
|US7994220||ALLERGAN||Milnacipran for the long-term treatment of fibromyalgia syndrome|| |
(6 years from now)
Market Authorisation Date: 14 January, 2009
Treatment: Management of fibromyalgia (fm); Management of fibromyalgia
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic